§ 26.169 Reporting Results.

(a) The HHS-certified laboratory shall report test results to the licensee’s or other entity’s MRO within 5 business days after receiving the specimen from the licensee or other entity. Before reporting any test result to the MRO, the laboratory’s certifying scientist shall certify the result as correct. The report must identify the substances for which testing was performed; the results of the validity and drug tests; the cutoff levels for each; any indications of tampering, adulteration, or substitution that may be present; the specimen identification number assigned by the licensee or

(b) The MRO, the laboratory, must produce a final report summarizing the results of the validity and drug tests. The report must include the following information:

(1) Specimen identification number;
(2) The result of each test performed;
(3) The cutoff levels used by the laboratory;
(4) Any indications of tampering, adulteration, or substitution that may be present;
(5) The laboratory’s certifying scientist’s certification of the result as correct;
(6) Any comments or recommendations.

(c) The MRO must review the final report and notify the licensee or other entity of any issues or concerns regarding the results.

(d) The MRO must maintain a record of all test results and reports, including the final report, for a period of not less than 10 years after the date of the test.

(e) The MRO must retain all specimens for a period of 3 years after the date of the test, unless the specimens are destroyed for legal reasons.

(f) The MRO must ensure that all laboratory personnel who handle specimens are trained in the proper procedures for handling and testing specimens.

(g) The MRO must institute a quality control program to ensure the accuracy and reliability of test results. The program must include regular monitoring of test results and corrective actions as necessary.

(h) The MRO must maintain a record of all quality control test results and any corrective actions taken.

(i) The MRO must ensure that all laboratory personnel who handle specimens are trained in the proper procedures for handling and testing specimens.

(j) The MRO must institute a quality control program to ensure the accuracy and reliability of test results. The program must include regular monitoring of test results and corrective actions as necessary.

(k) The MRO must maintain a record of all quality control test results and any corrective actions taken.

(l) The MRO must ensure that all laboratory personnel who handle specimens are trained in the proper procedures for handling and testing specimens.

(m) The MRO must institute a quality control program to ensure the accuracy and reliability of test results. The program must include regular monitoring of test results and corrective actions as necessary.

(n) The MRO must maintain a record of all quality control test results and any corrective actions taken.

(o) The MRO must ensure that all laboratory personnel who handle specimens are trained in the proper procedures for handling and testing specimens.

(p) The MRO must institute a quality control program to ensure the accuracy and reliability of test results. The program must include regular monitoring of test results and corrective actions as necessary.

(q) The MRO must maintain a record of all quality control test results and any corrective actions taken.

(r) The MRO must ensure that all laboratory personnel who handle specimens are trained in the proper procedures for handling and testing specimens.

(s) The MRO must institute a quality control program to ensure the accuracy and reliability of test results. The program must include regular monitoring of test results and corrective actions as necessary.

(t) The MRO must maintain a record of all quality control test results and any corrective actions taken.

(3) A false negative challenge. This blind performance test sample must contain a measurable amount of the target drug or analyte in concentrations ranging between 130 and 155 percent of the initial cutoff values;

(4) Adulterated. The adulterated blind performance test sample must have a pH of less than or equal to 2, or greater than or equal to 12, or a nitrite or other oxidant concentration equal to or greater than 500 mcg/mL, equal to or greater than 50 mcg/mL chromium (VI)-equivalents, or a halogen concentration equal to or greater than the LOD. Blind performance test samples for other adulterants must have adulterant concentrations equal to or greater than (or equal to or less than, as appropriate) the initial cutoff levels used by the licensee’s or other entity’s HHS-certified laboratory;

(5) Dilute. The dilute blind performance test sample must contain a creatinine concentration that is equal to or greater than 5 mg/dL but less than 20 mg/dL, and the specific gravity must be greater than 1.0010 but less than 1.0030; or

(6) Substituted. The substituted blind performance test sample must contain less than 2 mg/dL of creatinine, and the specific gravity must be less than or equal to 1.0010, or equal to or greater than 1.0200.

(h) In order to ensure that blind performance test samples continue to meet the criteria set forth in paragraph (g) of this section, licensees and other entities shall—

(1) Ensure that all blind performance test sample lots are placed in service by the supplier only after confirmation by an HHS-certified laboratory, and for no more than 6 months;

(2) Ensure that the supplier provides the expiration date for each blind performance test sample to ensure that each sample will have the expected value when it is submitted to and tested by a laboratory; and

(3) At a minimum, require the supplier to check each open lot bi-monthly (i.e., every two months) to ensure that samples remaining in the lot do not fall below 130 percent of the initial cutoff test concentration established by the assay manufacturer. Thus, for example, a lot that was certified by an HHS-certified laboratory at 155 percent of the manufacturer’s assay cutoff level, and was reported by the licensee’s or other entity’s HHS-certified laboratory to be at or above 130 percent of that standard is acceptable. A test that indicated a result below 130 percent of that standard would be unacceptable. Licensees and other entities shall discard blind performance test samples from any lot that is outside of these parameters and may not use any further samples from that lot.

(i) Licensees and other entities shall ensure that each blind performance test sample is indistinguishable to laboratory personnel from a donor’s specimen, as follows:

(1) The licensee or other entity shall submit blind performance test samples to the laboratory using the same channels (i.e., from the licensee’s or other entity’s collection site or licensee testing facility, as appropriate) through which donors’ specimens are sent to the laboratory;

(2) The collector and licensee testing facility personnel, as appropriate, shall use a custody-and-control form, place fictional initials on the specimen bottles’ labels/seals, and indicate for the MRO on the MRO’s copy that the specimen is a blind performance test sample; and

(3) The licensee or other entity shall ensure that all blind performance test samples include split samples, when the FFD program includes split specimen procedures.
other entity; and the specimen identification number assigned by the laboratory.

(b) If licensees or other entities specify cutoff levels for drugs or drug metabolites that are more stringent than those specified in this part, the laboratory need only conduct the more stringent tests and shall report the results of the initial and confirmatory tests only for the more stringent cutoff levels.

(c) The HHS-certified laboratory shall report as negative all specimens that are negative on the initial or confirmatory drug and validity tests. Specimens that test as positive, adulterated, substituted, dilute, or invalid on the confirmatory analysis must be reported to the MRO as positive for a specific drug(s) or drug metabolite(s), or as meeting the criteria for an adulterated, substituted, dilute, or invalid specimen.

(1) The laboratory shall report all positive, adulterated, substituted, dilute, and invalid test results for each specimen to the MRO. For example, a specimen may be both adulterated and positive for one or more specific drugs.

(2) For a specimen that has a positive test result, the laboratory shall provide numerical values if the MRO requests such information. The MRO’s request for positive confirmatory test results may be either a general request covering all such results or a specific case-by-case request. The laboratory shall routinely provide quantitative values for confirmatory opiate test results for morphine or codeine that are greater than or equal to 15,000 ng/mL, even if the MRO has not requested quantitative values for the test result.

(3) For a specimen that has an adulterated or substituted test result, the laboratory shall provide the MRO with the numerical values that support the reported result. The MRO may not disclose the numerical values to the licensee or other entity, except as permitted in §26.37(b). If the numerical values for creatinine are below the LOD, the laboratory shall report to the MRO “creatinine: none detected” (i.e., substituted) along with the numerical values of the specific gravity test.

(4) For a specimen that has an invalid result, the laboratory shall contact the MRO and both will decide whether testing by another certified laboratory would be useful in being able to report a positive or adulterated result. This contact may occur through any secure electronic means (e.g., telephone, fax, e-mail). If no further testing is necessary, the laboratory shall report the invalid result to the MRO.

(5) When the concentration of a drug, metabolite, or adulterant exceeds the linear range of the standard curve, the laboratory may report to the MRO that the quantitative value “exceeds the linear range of the test.” that the quantitative value is “equal to or greater than <insert the value for the upper limit of the linear range>,” or may report an accurate quantitative value above the upper limit of the linear range that was obtained by diluting an aliquot of the specimen.

(d) The MRO and MRO staff may not disclose quantitative test results to a licensee or other entity, but shall report only whether the specimen was positive (and for which analyte), adulterated, substituted, dilute, invalid, or negative, except as permitted under §26.37(b). This paragraph does not preclude either the HHS-certified laboratory or the MRO from providing program performance data, as required under §26.717.

(e) The laboratory may transmit results to the MRO by various electronic means (e.g., teleprinters, facsimile, or computer) in a manner designed to ensure the confidentiality of the information. The laboratory may not provide results orally by telephone. The licensee or other entity, directly or through the HHS-certified laboratory, shall ensure the security of the data transmission and ensure only authorized access to any data transmission, storage, and retrieval system.

(f) For negative test results, the HHS-certified laboratory may fax, courier, mail, or electronically transmit a computer-generated electronic report and/or a legible image or copy of the completed custody-and-control form to the MRO. However, for positive, adulterated, substituted, dilute, and invalid results, the laboratory shall fax, courier, mail, or electronically transmit a legible image or copy of the completed custody-and-control form to the MRO.
$(g)$ For a specimen that has a positive, adulterated, substituted, dilute, or invalid result, the laboratory shall retain the original custody-and-control form and transmit to the MRO a copy of the original custody-and-control form signed by a certifying scientist.

$(h)$ The HHS-certified laboratory shall provide to the licensee’s or other entity’s official responsible for coordination of the FFD program an annual statistical summary of urinalysis testing, which may not include any personal identifying information. To avoid sending data from which it is likely that information about a donor’s test result can be readily inferred, the laboratory may not send a summary report if the licensee or other entity has fewer than 10 specimen test results in a 1-year period. The summary report must include test results that were reported within the year period. The laboratory shall send the summary report to the licensee or other entity within 14 calendar days after the end of the 1-year period covered by the report. The statistics must be presented either for the cutoff levels specified in this part or for any more stringent cutoff levels that the licensee or other entity may specify. The HHS-certified laboratory shall make available quantitative results for all specimens tested when requested by the NRC, licensee, or other entity for whom the laboratory is performing drug-testing services. If the FFD program tests for additional drugs beyond those listed in §26.31(d), the summary must include drug test results for the additional drugs. The summary report must contain the following information:

1. Total number of specimens received;
2. Number of specimens reported as—
   1. Negative, and
   2. Negative and dilute;
3. Number of specimens reported as positive on confirmatory tests by drug or drug metabolite for which testing is conducted, including, but not limited to—
   1. Marijuana metabolite;
   2. Cocaine metabolite;
   3. Opiates (total);
   4. Codeine;
   5. Morphine; and
   6. AM;
   7. Phencyclidine;
   8. Amphetamines (total);
   9. Amphetamine;
   10. Methamphetamine;
   11. Total number of specimens reported as adulterated;
   12. Total number of specimens reported as substituted;
   13. Total number of specimens reported as positive and dilute (including an indication as to whether the specimen was subject to the special analysis permitted in §26.163(a)(2));
   14. Total number of specimens reported as invalid; and
   15. Number of specimens reported as rejected for testing and the reason for the rejection.

Subpart H—Determining Fitness-for-Duty Policy Violations and Determining Fitness

§26.181 Purpose.

This subpart contains requirements for determining whether a donor has violated the FFD policy and for making a determination of fitness.

§26.183 Medical review officer.

(a) Qualifications. The MRO shall be knowledgeable of this part and of the FFD policies of the licensees and other entities for whom the MRO provides services. The MRO shall be a physician holding either a Doctor of Medicine or Doctor of Osteopathy degree who is licensed to practice medicine by any State or Territory of the United States, the District of Columbia, or the Commonwealth of Puerto Rico. By March 31, 2010, the MRO shall have passed an examination administered by a nationally-recognized MRO certification board or subspecialty board for medical practitioners in the field of medical review of Federally mandated drug tests.

(b) Relationships. The MRO may be an employee of the licensee or other entity or a contractor. However, the MRO may not be an employee or agent of, or have any financial interest in, an HHS-certified laboratory or a contracted operator of a licensee testing facility for whom the MRO reviews drug test results. Additionally, the MRO may not derive any financial benefit by having